Found: 100
Select item for more details and to access through your institution.
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- letter
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 10, p. 2155, doi. 10.1007/s00125-018-4702-3
- By:
- Publication type:
- Article
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 8, p. 1712, doi. 10.1007/s00125-018-4644-9
- By:
- Publication type:
- Article
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
- Published in:
- Diabetologia, 2018, v. 61, n. 7, p. 1522, doi. 10.1007/s00125-018-4630-2
- By:
- Publication type:
- Article
Bladder cancer in the EMPA-REG OUTCOME trial.
- Published in:
- 2017
- By:
- Publication type:
- Letter
The kisspeptin-GnRH pathway in human reproductive health and disease.
- Published in:
- Human Reproduction Update, 2014, v. 20, n. 4, p. 485, doi. 10.1093/humupd/dmu009
- By:
- Publication type:
- Article
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
- By:
- Publication type:
- Article
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1886, doi. 10.1111/dom.14415
- By:
- Publication type:
- Article
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1173, doi. 10.1111/dom.14326
- By:
- Publication type:
- Article
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 425, doi. 10.1111/dom.14234
- By:
- Publication type:
- Article
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2335, doi. 10.1111/dom.14158
- By:
- Publication type:
- Article
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1151, doi. 10.1111/dom.14017
- By:
- Publication type:
- Article
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1141, doi. 10.1111/dom.14015
- By:
- Publication type:
- Article
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1207, doi. 10.1111/dom.13991
- By:
- Publication type:
- Article
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 631, doi. 10.1111/dom.13938
- By:
- Publication type:
- Article
Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 1, p. 136, doi. 10.1111/dom.13496
- By:
- Publication type:
- Article
Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2200, doi. 10.1111/dom.13352
- By:
- Publication type:
- Article
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2190, doi. 10.1111/dom.13351
- By:
- Publication type:
- Article
Brief Intervention in Type 1 diabetes -- Education for Self-efficacy (BITES): Protocol for a randomised control trial to assess biophysical and psychological effectiveness.
- Published in:
- BMC Endocrine Disorders, 2007, v. 7, p. 6, doi. 10.1186/1472-6823-7-6
- By:
- Publication type:
- Article
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
- Published in:
- 2020
- By:
- Publication type:
- journal article
162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-162-OR
- By:
- Publication type:
- Article
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-131-LB
- By:
- Publication type:
- Article
1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1224-P
- By:
- Publication type:
- Article
952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-952-P
- By:
- Publication type:
- Article
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1144-P
- By:
- Publication type:
- Article
28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-28-OR
- By:
- Publication type:
- Article
2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-2216-PUB
- By:
- Publication type:
- Article
1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1-OR
- By:
- Publication type:
- Article
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-159-LB
- By:
- Publication type:
- Article
1225-P: The Association between Long-Term Glucose Variability (GV), Cardiovascular (CV) Death, and Heart Failure (HF) Outcomes in the EMPA-REG OUTCOME Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1225-P
- By:
- Publication type:
- Article
1199-P: Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1199-P
- By:
- Publication type:
- Article
1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1198-P
- By:
- Publication type:
- Article
432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-432-P
- By:
- Publication type:
- Article
388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-388-P
- By:
- Publication type:
- Article
248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-248-OR
- By:
- Publication type:
- Article
19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-19-LB
- By:
- Publication type:
- Article
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
- Published in:
- 2019
- By:
- Publication type:
- letter
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
- Published in:
- European Journal of Heart Failure. Supplements, 2017, v. 19, n. 11, p. 1390, doi. 10.1002/ejhf.933
- By:
- Publication type:
- Article
Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions.
- Published in:
- Practical Diabetes, 2015, v. 32, n. 8, p. 301, doi. 10.1002/pdi.1976
- By:
- Publication type:
- Article
The Young Diabetologists' Forum post-CCT project: what does it mean for trainers and trainees?
- Published in:
- Practical Diabetes, 2012, v. 29, n. 9, p. 353, doi. 10.1002/pdi.1721
- By:
- Publication type:
- Article